Literature DB >> 21402247

Prognostic utility of NT-proBNP in acute exacerbations of chronic pulmonary diseases.

Araceli Molina Medina1, Marta Sanchez Marteles, Elisa Bermejo Sáiz, Sandra Serrano Martínez, Fernando Ruiz Laiglesia, José A Nieto Rodríguez, Juan I Pérez-Calvo.   

Abstract

BACKGROUND: The prognostic value of NT-proBNP levels in patients admitted to hospital due to acute exacerbations of chronic pulmonary diseases (CPDs) is unknown.
SETTING: Internal Medicine units at two general hospitals.
METHODS: NT-proBNP levels were obtained within 72 h after admission in 192 consecutive patients with acute exacerbations of CPDs and no history of heart failure or diuretic treatment. Clinical characteristics and main outcomes were assessed over a 12-month follow-up. NT-proBNP cut-points for outcomes were obtained by ROC (receiver operating characteristics) curve analysis.
RESULTS: Chronic obstructive lung disease (69.3%) and chronic asthma (22.4%) were the most prevalent CPDs, and non-pneumonic acute respiratory infection (72.4%) and pneumonia (22.9%) were the most frequent causes of exacerbation. Atrial flutter or fibrillation rate was 11%. During the one-year follow-up period, 22 patients died, 42 were re-admitted, 46 received new long-term oxygen therapy, and 39 received new diuretic treatment. NT-proBNP values correlated with hospitalisation days. NT-proBNP values over 587.9 pg/ml were associated with significantly raised one-year mortality (OR=3.90; 95% IC 1.46-10.47; p=0.006) and over 782.2 pg/ml with cardio-pulmonary deaths (OR=6.38; 95% IC 1.91-21.3; p=0.002). That association persisted after adjustment for age, gender, creatinine levels and cardiac rhythm. NT-proBNP values over 628.7 pg/ml were associated with significantly higher probability of new diuretic treatment (OR=4.38; IC 95% 2.07-9.25; p<0.001). The negative predictive values for these cut-points ranged from 89% to 97%.
CONCLUSION: NT-proBNP levels below 587.9 pg/ml in patients with acute exacerbations of CPD were associated with favourable one-year outcomes.
Copyright © 2010 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21402247     DOI: 10.1016/j.ejim.2010.12.002

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  16 in total

1.  NT-proBNP in stable COPD and future exacerbation risk: Analysis of the SPIROMICS cohort.

Authors:  Wassim W Labaki; Meng Xia; Susan Murray; Jeffrey L Curtis; R Graham Barr; Surya P Bhatt; Eugene R Bleecker; Nadia N Hansel; Christopher B Cooper; Mark T Dransfield; J Michael Wells; Eric A Hoffman; Richard E Kanner; Robert Paine; Victor E Ortega; Stephen P Peters; Jerry A Krishnan; Russell P Bowler; David J Couper; Prescott G Woodruff; Fernando J Martinez; Carlos H Martinez; MeiLan K Han
Journal:  Respir Med       Date:  2018-06-05       Impact factor: 3.415

2.  N-Terminal Prohormone of Brain Natriuretic Peptide (NT-proBNP) as a Diagnostic Biomarker of Left Ventricular Systolic Dysfunction in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AECOPD).

Authors:  Ilija Andrijevic; Senka Milutinov; Zagorka Lozanov Crvenkovic; Jovan Matijasevic; Ana Andrijevic; Tomi Kovacevic; Darijo Bokan; Bojan Zaric
Journal:  Lung       Date:  2018-06-27       Impact factor: 2.584

3.  Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity.

Authors:  John T Parissis; Chiara Andreoli; Nikolaos Kadoglou; Ignatios Ikonomidis; Dimitrios Farmakis; Ioanna Dimopoulou; Efstathios Iliodromitis; Maria Anastasiou-Nana; Mitja Lainscak; Giussepe Ambrosio; Alexandre Mebazaa; Gerasimos Filippatos; Ferenc Follath
Journal:  Clin Res Cardiol       Date:  2014-04-10       Impact factor: 5.460

Review 4.  Acute exacerbation of chronic obstructive pulmonary disease: cardiovascular links.

Authors:  Cheryl R Laratta; Stephan van Eeden
Journal:  Biomed Res Int       Date:  2014-03-02       Impact factor: 3.411

5.  Standardized evaluation of lung congestion during COPD exacerbation better identifies patients at risk of dying.

Authors:  Arne Didrik Høiseth; Torbjørn Omland; Bo Daniel Karlsson; Pål H Brekke; Vidar Søyseth
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2013-12-05

6.  The clinical value of serial measurement of high-sensitivity cardiac troponin T in acute exacerbations ofchronic obstructive pulmonary disease.

Authors:  Arne Didrik Høiseth; Anke Neukamm; Tor-Arne Hagve; Torbjørn Omland; Pål H Brekke; Vidar Søyseth
Journal:  Open Heart       Date:  2014-01-15

Review 7.  Expert consensus document: Echocardiography and lung ultrasonography for the assessment and management of acute heart failure.

Authors:  Susanna Price; Elke Platz; Louise Cullen; Guido Tavazzi; Michael Christ; Martin R Cowie; Alan S Maisel; Josep Masip; Oscar Miro; John J McMurray; W Frank Peacock; F Javier Martin-Sanchez; Salvatore Di Somma; Hector Bueno; Uwe Zeymer; Christian Mueller
Journal:  Nat Rev Cardiol       Date:  2017-04-27       Impact factor: 32.419

8.  Significance of NT-pro-BNP in acute exacerbation of COPD patients without underlying left ventricular dysfunction.

Authors:  Muhammad Adrish; Varalaxmi Bhavani Nannaka; Edison J Cano; Bharat Bajantri; Gilda Diaz-Fuentes
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-04-13

9.  NT-proBNP independently predicts long term mortality after acute exacerbation of COPD - a prospective cohort study.

Authors:  Arne Didrik Høiseth; Torbjørn Omland; Tor-Arne Hagve; Pål H Brekke; Vidar Søyseth
Journal:  Respir Res       Date:  2012-10-29

Review 10.  Amino terminal pro brain natriuretic peptide predicts all-cause mortality in patients with chronic obstructive pulmonary disease: Systematic review and meta-analysis.

Authors:  Rita Pavasini; Guido Tavazzi; Simone Biscaglia; Federico Guerra; Alessandro Pecoraro; Fatima Zaraket; Francesco Gallo; Giosafat Spitaleri; Marco Contoli; Roberto Ferrari; Gianluca Campo
Journal:  Chron Respir Dis       Date:  2016-12-15       Impact factor: 2.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.